P123 - REDUCING PARENTERAL SUPPORT: PATIENT AND HEALTHCARE PROFESSIONAL PREFERENCES FOR POTENTIAL NEW SHORT BOWEL SYNDROME THERAPIES

P123

REDUCING PARENTERAL SUPPORT: PATIENT AND HEALTHCARE PROFESSIONAL PREFERENCES FOR POTENTIAL NEW SHORT BOWEL SYNDROME THERAPIES

S.-M. Jafri¹, J. E. Harrison², V. Kumpf³, G. Mitchell⁴, D. Wolin⁵, L. Zografos⁵, M. Yang⁴, L. Jackson⁵, J. Wang⁵, J. Henderson⁴, M. Boules^4,*, R. Vemulapalli⁶

¹Henry Ford Hospital, Detroit, ²Girls with Guts, Philadelphia, ³Vanderbilt University Medical Center, Nashville, ⁴Ironwood Pharmaceuticals, Inc., Boston, ⁵RTI Health Solutions, Durham, ⁶UT Southwestern Medical Center, Dallas, United States

Rationale: Understanding patient and healthcare provider (HCP) preferences for treatment and outcome attributes in patients with short bowel syndrome (SBS) dependent on parenteral support (PS) can inform management strategies and therapeutic advancements.

Methods: A noninterventional, cross-sectional, online survey evaluating potential new treatment and outcome attributes was conducted in the US and Europe in patients with SBS on parenteral support (≥18 years at diagnosis) and HCPs with ≥2 years of SBS experience managing ≥1 patient.

Results: Responses were collected from 91 patients and 336 HCPs. Patients’ mean age was 50.4 years (58.2% female; 69.1% White). Patients were on total parenteral nutrition (TPN; 90.1%) and/or IV hydration (73.6%) and glucagon-like peptide-2 analog therapy (24.2%); 42.3% of HCPs were physicians.

Among patients, outcome attributes rated as very important included minimizing TPN (70.3%), IV hydration/nutrition (64.8%), and side effects (68.1%). Most (67.0%) considered a days/week TPN decrease meaningful, including a 1–2 days/week decrease (33.0%). 63.3% rated minimizing injection frequency as very important.

For HCPs, among attributes rated as very important, top priorities were reducing TPN central venous access need/related risks (73.5%), hospitalizations (72.8%), and injection frequency (63.4%). Reducing TPN was meaningful to 95.8% of HCPs, including a 1–2 days/week decrease (44.3%).

Conclusion: Patients highly rated reducing TPN dependence/associated risks, with even a 1 day/week TPN reduction considered meaningful, and decreasing injection frequency for potential new SBS therapies. HCPs valued reducing central venous access need/related risks, hospitalizations, and injection frequency. These findings highlight critical unmet needs in SBS management and the importance of therapies that reduce PS burden and side effects, leading to improved patient outcomes.

Disclosure of Interest: S.-M. Jafri Consultant for: Intercept, Ironwood, AbbVie, Gilead, Takeda, and Ipsen, J. Harrison Other: Volunteer for Girls With Guts, V. Kumpf Consultant for: Ironwood, Baxter Healthcare, and Fresenius Kabi, G. Mitchell Other: Employee of Ironwood and may hold shares and/or stock options in the company., D. Wolin Other: Full-time employee of RTI Health Solutions, an independent nonprofit research organization, which was retained by Ironwood to conduct the research that is the subject of this abstract. Their compensation is unconnected to the studies on which they work. , L. Zografos Other: Full-time employee of RTI Health Solutions, an independent nonprofit research organization, which was retained by Ironwood to conduct the research that is the subject of this abstract. Their compensation is unconnected to the studies on which they work. , M. Yang Other: Employee of Ironwood and may hold shares and/or stock options in the company., L. Jackson Other: Full-time employee of RTI Health Solutions, an independent nonprofit research organization, which was retained by Ironwood to conduct the research that is the subject of this abstract. Their compensation is unconnected to the studies on which they work. , J. Wang Other: Full-time employee of RTI Health Solutions, an independent nonprofit research organization, which was retained by Ironwood to conduct the research that is the subject of this abstract. Their compensation is unconnected to the studies on which they work. , J. Henderson Other: Employee of Ironwood and may hold shares and/or stock options in the company., M. Boules Other: Employee of Ironwood and may hold shares and/or stock options in the company., R. Vemulapalli Other: CME Faculty for Novus Medical Education